Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Allergy: European Journal of Allergy and Clinical Immunology
DOIs	https://doi.org/10.1111/all.14235
Publication status	Published - 16 Feb 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{42f17415fc0848ffab3d86604a419879,

title = "Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma",

author = "Liam O'Mahony",

year = "2020",

month = feb,

day = "16",

doi = "10.1111/all.14235",

language = "English",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma

AU - O'Mahony, Liam

PY - 2020/2/16

Y1 - 2020/2/16

UR - http://dx.doi.org/10.1111/all.14235

U2 - 10.1111/all.14235

DO - 10.1111/all.14235

M3 - Article

SN - 0105-4538

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

ER -